LyGenesis has filed a notice of an exempt offering of securities to raise $20,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, LyGenesis is raising $20,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Michael Hufford played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About LyGenesis
LyGenesis is a biotechnology company with an organ regeneration technology platform enabling a patients lymph nodes to be used as bioreactors to regrow functioning ectopic organs. LyGenesis lead preclinical program is focused on liver regeneration for patients with end stage liver disease. Other therapeutic targets for organ regeneration include the thymus, pancreas, and kidney. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania.
To learn more about LyGenesis, visit http://www.lygenesis.com/
Contact:
Michael Hufford, Chief Executive Officer
412-449-9983
https://www.linkedin.com/in/michael-hufford-4339596/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.